Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2025
2025-12-31

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2025

Voluntary and Business Update Announcement Innovative Drug Oral Small-molecule JAK1 Inhibitor Povorcitinib Included In The List Of Breakthrough Therapeutic Drugs
2025-12-15

Voluntary and Business Update Announcement Innovative Drug Oral Small-molecule JAK1 Inhibitor Povorcitinib Included In The List Of Breakthrough Therapeutic Drugs

Voluntary and Business Update Announcement New Drug Application of Class 1 Innovative Drug Y-3 for Injection for Acute Ischemic Stroke Accepted in China
2025-12-11

Voluntary and Business Update Announcement New Drug Application of Class 1 Innovative Drug Y-3 for Injection for Acute Ischemic Stroke Accepted in China

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2025
2025-12-01

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2025

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2025
2025-10-31

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2025

Voluntary and Business Update Announcement New Drug Application for Atopic Dermatitis Indication of Long-acting Anti-IL-4Rα Humanized Monoclonal Antibody Injection Accepted in China
2025-10-30

Voluntary and Business Update Announcement New Drug Application for Atopic Dermatitis Indication of Long-acting Anti-IL-4Rα Humanized Monoclonal Antibody Injection Accepted in China

Voluntary and Business Update Announcement Signing a Distribution Agreement for Ophthalmic Drugs Lucentis® and Beovu®
2025-10-27

Voluntary and Business Update Announcement Signing a Distribution Agreement for Ophthalmic Drugs Lucentis® and Beovu®

Voluntary and Business Update Announcement Approval of Drug Clinical Trials for Additional Chronic Obstructive Pulmonary Disease Indication of Class 1 Innovative Drug MG-K10 Humanized Monoclonal Antibody Injection
2025-09-30

Voluntary and Business Update Announcement Approval of Drug Clinical Trials for Additional Chronic Obstructive Pulmonary Disease Indication of Class 1 Innovative Drug MG-K10 Humanized Monoclonal Antibody Injection

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2025

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2025

Voluntary and Business Update Announcement Approval of Phase III Drug Clinical Trials for Additional Chronic Spontaneous Urticaria Indication of Class 1 Innovative Drug MG-K10 Humanized Monoclonal Antibody Injection
2025-09-28

Voluntary and Business Update Announcement Approval of Phase III Drug Clinical Trials for Additional Chronic Spontaneous Urticaria Indication of Class 1 Innovative Drug MG-K10 Humanized Monoclonal Antibody Injection

Voluntary and Business Update Announcement Positive Results from Phase 3 Clinical Trial of Ruxolitinib Cream in Chinese Patients with Atopic Dermatitis
2025-09-26

Voluntary and Business Update Announcement Positive Results from Phase 3 Clinical Trial of Ruxolitinib Cream in Chinese Patients with Atopic Dermatitis

Voluntary and Business Update Announcement Approval of Drug Clinical Trials for Uterine Fibroids Indication of Innovative Drug GnRH Receptor Antagonist CMS-D002

Voluntary and Business Update Announcement Approval of Drug Clinical Trials for Uterine Fibroids Indication of Innovative Drug GnRH Receptor Antagonist CMS-D002